According to GlobalData’s medical device pipeline database, 23 Artificial Lung devices are in various stages of development globally. GlobalData’s report Artificial Lung provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 17 are in active development, while the remaining six are in an inactive stage of development. There are 14 products in the early stages of development, and the remaining three are in the late stages of development.
Anesthesia and respiratory devices include devices used in administering anesthesia during surgery, devices used in respiratory assistance and respiratory function measurement. An artificial lung (AL) is a device that can temporarily take over the function of the lungs in people with severe respiratory failure. Artificial Lung provides oxygen to the blood and removing carbon dioxide from the blood.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Artificial Lung pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Artificial Lung devices. Overall, most of these Artificial Lung pipeline devices are being developed by private entities.
Key players involved in the active development of Artificial Lung include McGowan Institute for Regenerative Medicine, University of Pittsburgh, Veterans Health Administration, ALung Technologies, Belluscura, Breethe, Case Western Reserve University, Collplant Biotechnologies, enmodes and Lung Biotechnology PBC.
For a complete picture of the developmental pipeline for Artificial Lung devices, buy the report here.